Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes

Diabetes

Volumn 61, Issue 12, 2012, Pages 3270-3279

  Hazra, Sugata ^a   Rasheed, Adil ^b   Bhatwadekar, Ashay ^a   Wang, Xiaoxin ^c   Shaw, Lynn C ^a   Patel, Monika ^b   Caballero, Sergio ^a   Magomedova, Lilia ^b   Solis, Nathaniel ^c   Yan, Yuanqing ^a   Wang, Weidong ^c   Thinschmidt, Jeffrey S ^a   Verma, Amrisha ^d   Li, Qiuhong ^d   Levi, Moshe ^c   Cummins, Carolyn L ^b   Grant, Maria B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; LIGAND; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CELL FUNCTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOTHELIAL PROGENITOR CELL; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID DIET; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; BENZOATES; BENZYLAMINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; MALE; MICE; MICE, KNOCKOUT; ORPHAN NUCLEAR RECEPTORS; STEM CELLS;

EID: 84870368611     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1596     Document Type: Article

References (50)

1. Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:1513-1518
2. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-731 (Pubitemid 26360651)
3. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-614 (Pubitemid 43326865)
4. Faulds MH, Zhao C, Dahlman-Wright K. Molecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseases. Curr Opin Pharmacol 2010;10:692-697
5. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002;99: 7604-7609 (Pubitemid 34568738)
6. Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res 2011;2:96-103
7. Brucklacher RM, Patel KM, VanGuilder HD, et al. Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genomics 2008;1:26
8. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007;2007:95103
9. Kowluru RA, Kanwar M, Chan PS, Zhang JP. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Arch Ophthalmol 2008;126:1266-1272
10. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based antiinflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007;56:337-345
11. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 2007;56:224-230
12. Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011;96:287-294
13. Verma A, Shan Z, Lei B, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther 2012;20:28-36
14. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-353 (Pubitemid 39100452)
15. Sekiguchi H, Ii M, Losordo DW. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol 2009;219:235-242
16. Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011;29:1650-1655
17. Grant MB, May WS, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002;8:607-612 (Pubitemid 34633439)
18. Caballero S, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 2007;56:960-967 (Pubitemid 46525067)
19. Egan CG, Lavery R, Caporali F, et al. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 2008;51:1296-1305
20. Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004;53:195-199 (Pubitemid 38044715)
21. Loomans CJ, van Haperen R, Duijs JM, et al. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol Med 2009;15:152-159
22. Erusalimsky JD. Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol 2009;106:326-332
23. Frey RS, Ushio-Fukai M, Malik AB. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009;11:791-810
24. Jarajapu YP, Caballero S, Verma A, et al. Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells. Invest Ophthalmol Vis Sci 2011;52:5093-5104
25. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49:185-192 (Pubitemid 46360359)
26. Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 2010;59:2916-2927
27. Bhatwadekar A, Glenn JV, Figarola JL, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol 2008;92:545-547 (Pubitemid 351497988)
28. Li Q, Verma A, Han PY, et al. Diabetic eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci 2010;51:5240-5246
29. Pan H, Nguyen NQ, Yoshida H, et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 2004;45:2413-2419 (Pubitemid 38902617)
30. Patel R, Patel M, Tsai R, et al. LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest 2011;121:431-441
31. Wollam J, Magomedova L, Magner DB, et al. The Rieske oxygenase DAF-36 functions as a cholesterol 7-desaturase in steroidogenic pathways governing longevity. Aging Cell 2011;10:879-884
32. Schuettauf F, Rejdak R, Walski M, et al. Retinal neurodegeneration in the DBA/2J mouse-a model for ocular hypertension. Acta Neuropathol 2004; 107:352-358 (Pubitemid 38477362)
33. Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 2007;117:2337-2346 (Pubitemid 47219578)
34. Cummins CL, Volle DH, Zhang Y, et al. Liver X receptors regulate adrenal cholesterol balance. J Clin Invest 2006;116:1902-1912 (Pubitemid 44033314)
35. Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998;93:693-704 (Pubitemid 28257577)
36. Kalaany NY, Gauthier KC, Zavacki AM, et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab 2005;1:231-244 (Pubitemid 43960607)
37. Croce G, Passacquale G, Necozione S, Ferri C, Desideri G. Nonpharmacological treatment of hypercholesterolemia increases circulating endothelial progenitor cell population in adults. Arterioscler Thromb Vasc Biol 2006;26:e38-e39 (Pubitemid 43732094)
38. Pirro M, Bagaglia F, Paoletti L, Razzi R, Mannarino MR. Hypercholesterolemia-associated endothelial progenitor cell dysfunction. Ther Adv Cardiovasc Dis 2008;2:329-339
39. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia [retracted in: Clin Sci (Lond) 2010;119:545]. Clin Sci (Lond) 2004;107:273-280 (Pubitemid 39243886)
40. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7
41. Fadini GP, Albiero M, Boscaro E, et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int 2010;34:709-715
42. Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol 2004;31:407-413 (Pubitemid 39044118)
43. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405 (Pubitemid 32730786)
44. Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011;121:4138-4149
45. Dwyer MA, Kazmin D, Hu P, McDonnell DP, Malek G. Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration. Mol Endocrinol 2011;25: 360-372
46. Zheng L, Gong B, Hatala DA, Kern TS. Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci 2007;48:361-367 (Pubitemid 47251425)
47. Li Calzi S, Purich DL, Chang KH, et al. Carbon monoxide and nitric oxide mediate cytoskeletal reorganization in microvascular cells via vasodilator-stimulated phosphoprotein phosphorylation: evidence for blunted responsiveness in diabetes. Diabetes 2008;57:2488-2494
48. Segal MS, Shah R, Afzal A, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006;55:102-109 (Pubitemid 43343304)
49. Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT-the emergence of new treatment options. J Clin Hypertens (Greenwich) 2002;4:52-57 (Pubitemid 34163047)
50. Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009;32:533-536